Mascarenhas, L., Meyer, W. H., Lyden, E., Rodeberg, D. A., Indelicato, D. J., Linardic, C. M., … Hawkins, D. S. (2014). Randomized phase II trial of bevacizumab and temsirolimus in combination with vinorelbine (V) and cyclophosphamide (C) for first relapse/disease progression of rhabdomyosarcoma (RMS): A report from the Children’s Oncology Group (COG). In Journal of Clinical Oncology (Vol. 32, pp. 10003–10003). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2014.32.15_suppl.10003

Mascarenhas, Leo, William H. Meyer, Elizabeth Lyden, David A. Rodeberg, Daniel Joseph Indelicato, Corrine M. Linardic, James Robert Anderson, and Douglas S. Hawkins. “Randomized phase II trial of bevacizumab and temsirolimus in combination with vinorelbine (V) and cyclophosphamide (C) for first relapse/disease progression of rhabdomyosarcoma (RMS): A report from the Children’s Oncology Group (COG).” In Journal of Clinical Oncology, 32:10003–10003. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.10003.

Mascarenhas L, Meyer WH, Lyden E, Rodeberg DA, Indelicato DJ, Linardic CM, et al. Randomized phase II trial of bevacizumab and temsirolimus in combination with vinorelbine (V) and cyclophosphamide (C) for first relapse/disease progression of rhabdomyosarcoma (RMS): A report from the Children’s Oncology Group (COG). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 10003–10003.

Mascarenhas, Leo, et al. “Randomized phase II trial of bevacizumab and temsirolimus in combination with vinorelbine (V) and cyclophosphamide (C) for first relapse/disease progression of rhabdomyosarcoma (RMS): A report from the Children’s Oncology Group (COG).” Journal of Clinical Oncology, vol. 32, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2014, pp. 10003–10003. Crossref, doi:10.1200/jco.2014.32.15_suppl.10003.

Mascarenhas L, Meyer WH, Lyden E, Rodeberg DA, Indelicato DJ, Linardic CM, Anderson JR, Hawkins DS. Randomized phase II trial of bevacizumab and temsirolimus in combination with vinorelbine (V) and cyclophosphamide (C) for first relapse/disease progression of rhabdomyosarcoma (RMS): A report from the Children’s Oncology Group (COG). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 10003–10003.